Allogene Therapeutics
Ann-Jay Tong is a Principal Scientist at Allogene Therapeutics since April 2023, with a strong background in mRNA-based vaccine development and individualized neoantigen-specific therapies. Prior experience includes serving as a Scientist 3 at Genentech from August 2016 to March 2023, focusing on single cell technologies for analyzing anti-tumor T cell responses and innate immune responses to nucleic acids. Ann-Jay was a Postdoctoral Fellow at UC Berkeley, studying innate immunity in lymphocytes and Toll-like receptors. As a Graduate Student Researcher at UCLA, a Ph.D. in Molecular Biology and Immunology was earned, focusing on transcriptional regulation during innate immune responses, alongside extensive work with RNAseq and other NGS approaches. Early career experience includes a role as a Lab Technician at the California Institute for Medical Research from June 2006 to July 2008. Ann-Jay holds a Bachelor of Arts in Molecular and Cell Biology from the University of California, Berkeley.
This person is not in the org chart
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.